# reload+after+2024-01-21 06:47:56.472630
address1§64 Sidney Street
city§Cambridge
state§MA
zip§02139
country§United States
phone§857 259 5340
website§https://www.voyagertherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§125
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Alfred W. Sandrock Jr., M.D., Ph.D.', 'age': 65, 'title': 'President, CEO & Director', 'yearBorn': 1958, 'fiscalYear': 2022, 'totalPay': 825414, 'exercisedValue': 0, 'unexercisedValue': 22935}, {'maxAge': 1, 'name': 'Mr. Peter P. Pfreundschuh CPA', 'age': 54, 'title': 'Chief Financial Officer', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 172729, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Krystof  Bankiewicz M.D., Ph.D.', 'title': 'Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Guangping  Gao Ph.D.', 'title': 'Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Mark A. Kay M.D., Ph.D.', 'age': 64, 'title': 'Founder', 'yearBorn': 1959, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Phillip D. Zamore Ph.D.', 'title': 'Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Robin  Swartz', 'age': 52, 'title': 'Chief Operating Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Todd  Carter Ph.D.', 'age': 53, 'title': 'Chief Scientific Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Jacquelyn Fahey Sandell Esq., J.D.', 'title': 'Chief Legal Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Michelle Quinn Smith', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.997
priceToSalesTrailing12Months§2.5783157
currency§USD
dateShortInterest§1702598400
forwardEps§-1.9
exchange§NMS
quoteType§EQUITY
shortName§Voyager Therapeutics, Inc.
longName§Voyager Therapeutics, Inc.
firstTradeDateEpochUtc§1447252200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§f7ecf33b-4e90-3ae3-af92-cfb97c2071f4
gmtOffSetMilliseconds§-18000000
targetHighPrice§18.0
targetLowPrice§11.0
targetMeanPrice§15.5
targetMedianPrice§16.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§4.153
grossMargins§0.48883998
ebitdaMargins§0.29879
trailingPegRatio§None
